Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. - Wikidata - thesis-toulmin - TriplyDB

Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer.

Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer.

http://www.wikidata.org/entity/Q36243296

about

The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate Cancer Non-Coding RNAs in Castration-Resistant Prostate Cancer: Regulation of Androgen Receptor Signaling and Cancer Metabolism Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer Quo vadis: advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapies Emerging methods for disease monitoring in malignant gliomas Using circulating tumor cells to inform on prostate cancer biology and clinical utility Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3 Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.Blood-based biomarkers for malignant gliomas Predicting time to castration resistance in hormone sensitive prostate cancer by a personalization algorithm based on a mechanistic model integrating patient data.From bench to bedside: the realities of reducing global prostate cancer disparity in black men.Epithelial mesenchymal transition (EMT) in prostate growth and tumor progression Predictive value of Sp1/Sp3/FLIP signature for prostate cancer recurrence.Vicious cycle of TGF-β signaling in tumor progression and metastasis.Potential utility of cancer-specific biomarkers for assessing response to hormonal treatments in metastatic prostate cancer.BMI1, stem cell factor acting as novel serum-biomarker for Caucasian and African-American prostate cancer.Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients Serum follicle-stimulating hormone levels predict time to development of castration-resistant prostate cancer.Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer.Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer Biochemical markers of bone turnover in patients with spinal metastases after resistance training under radiotherapy--a randomized trial.Prostate cancer - a biomarker perspective.Association of early PSA decline and time to PSA progression in abiraterone acetate-treated metastatic castration-resistant prostate cancer; a post-hoc analysis of Japanese phase 2 trials.Novel therapies for the treatment of advanced prostate cancer.Influence of Long-Distance Bicycle Riding on Serum/Urinary Biomarkers of Prostate Cancer.Perspectives on treatment of metastatic castration-resistant prostate cancer.Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall Survival Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study.Prognostic factors in Chinese patients with metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy.Targeted α-particle therapy of bone metastases in prostate cancer Prediction of PSA Progression in Castration-Resistant Prostate Cancer Based on Treatment-Associated Change in Tumor Burden Quantified by 18F-Fluorocholine PET/CT Combined overexpression of HIVEP3 and SOX9 predicts unfavorable biochemical recurrence-free survival in patients with prostate cancer.Optimal therapy sequencing in metastatic castration-resistant prostate cancer.Controversies in circulating tumor cell count during therapy.Circulating tumour cells: insights into tumour heterogeneity.Current, new and novel therapy for castration-resistant prostate cancer.Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer.Challenges in the sequencing of therapies for the management of metastatic castration-resistant prostate cancer.Prostate cancer: measuring PSA.

P2860

Q26738703-BA0FD8A5-0250-42DA-BD2A-E21B68C4C54B Q26774456-86A202DE-A8A7-4F1F-BE1A-CF7C0788D555 Q27010542-9BA3AC95-0E56-4837-825E-6E86069B8F7B Q27011642-1E676E50-9B8B-4946-B586-FC7C6A370E9F Q27023823-FC84703C-CE78-49C3-9B6B-4F3DDD509BFB Q28083261-34B0D564-938A-4C6E-B313-321E49C8ED5D Q30277291-D6EACEF8-B392-4198-AC17-51A2765E3B32 Q30574916-4CE70FBB-F24E-41A9-BB1F-0DB39378A093 Q30625411-4D2E7FFE-02FD-41E4-8880-D43B44BB57BC Q30999241-ABDD3B9D-90D1-495D-B35C-F5D78182CFA6 Q34135132-1C35E544-CC7E-4193-9C34-BA6466CED11A Q34397291-F75259E6-23E6-41C6-86C7-AF70B288C9E7 Q34427649-40BC2046-924F-4B9E-ABA3-527C79B8CAB2 Q34448186-9CFC25D1-99F5-4F11-BAAD-64405132795A Q34536729-B5388A34-E863-4F79-AD45-EDAC962EB94C Q34544617-14F8BEA2-1B5C-444A-B852-179A543EEAFB Q35655761-2C41DF6C-CBCE-4473-861B-981ACF002BF9 Q35683334-33AD1339-B6E4-4989-8BCD-9702B9D65E83 Q35879087-1E02A2AA-C403-4816-A588-22ADC513F02E Q35938840-2C76F623-DE55-4767-89DE-1645ABCBAC49 Q35956276-CEA4000F-F60D-4F44-89D3-CAABC4F46445 Q35959956-01BA1BF3-B825-464A-BCDA-B21B635D84B4 Q35992814-9DF4420F-B93D-4EB4-BB26-C68C696CBF59 Q36045735-25464496-E1D2-4F4F-9877-D472FF5AA7A9 Q36665708-971AA492-51DD-47B4-8F79-842CA76AC0BC Q36743703-BC1FCBDB-8E24-4AA0-8D66-BA8F1F0FE808 Q36871685-114101B0-39D8-42B3-8824-D26B83075866 Q36909750-9ACC3DA2-12B5-4E9E-BEFF-9B8882DB6889 Q37003299-401682EF-9ECA-4E4F-8646-724196C7E55A Q37084145-0692D0E6-149D-4700-9D3C-F9E3437CB981 Q37417656-F1114E93-D8C7-4180-8537-F7D3FB2B207A Q37496697-A757196C-CDBF-45B8-A619-38E14DED40C2 Q37537822-545B4936-100D-4BE5-B5C5-2811AAF9BDB7 Q38097373-30E32B16-3650-4ED3-8C72-4FDB7D68AFCF Q38115624-961BE017-6BA5-4273-99EC-E0B69D46CB9B Q38120824-04018FFB-4C98-48C3-B6CD-EF5DC63E1E6A Q38123202-B8D014EB-5ED8-4072-9F17-03F069BAF144 Q38183819-B1F2C2A5-5B18-4D33-90F5-7CE7DB470B81 Q38205964-DDCD9051-A8DA-427D-A0D4-5269E271CFE7 Q38210857-1B8215E6-E9D4-4820-A840-83E4E48183A0

P2860

Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer.

http://www.wikidata.org/entity/Q36243296

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Biomarkers in the management a ...... ion-resistant prostate cancer.

@ast

Biomarkers in the management a ...... ion-resistant prostate cancer.

@en

type

label

Biomarkers in the management a ...... ion-resistant prostate cancer.

@ast

Biomarkers in the management a ...... ion-resistant prostate cancer.

@en

prefLabel

Biomarkers in the management a ...... ion-resistant prostate cancer.

@ast

Biomarkers in the management a ...... ion-resistant prostate cancer.

@en

P1433

Q36243296-F0A59CB5-A9D6-47E1-86BF-96782D53A978

P1476

Q36243296-C3A23492-4B39-4D36-8191-D732EBF4A346

P2093

Q36243296-48006F7F-2331-4104-95CC-747D0888C45C

Q36243296-50F9C1DB-F7D8-4A43-9E68-5836CBFD95B4

Q36243296-63AE111D-0D7B-4202-878F-4D8346CE71C6

Q36243296-99C20998-E2B7-47D6-8A9C-81B100085DBF

Q36243296-C8CBF8C6-9C7E-41F2-AAFB-AE96A4ABC36C

Q36243296-D090F1B8-D982-4F0E-907E-2F3FC792954E

Q36243296-FE09F26A-D7FE-4699-B012-B161EDC4629E

Q36243296-FE4D7F1C-CA08-4B08-94D7-E63FFA52B134

P2860

Q36243296-0C15576D-B1B6-4058-BD4F-A25EAE8C262B

Q36243296-13815B06-2908-47CA-A0B2-D3D1A9EDB7BC

Q36243296-1A2AC5A6-F0E3-470A-AE04-239EFD2F6117

Q36243296-1E26309E-D886-42C6-BD4D-D27B458FDFBC

Q36243296-2BB22216-DB00-4196-8DF9-242495DA55D7

Q36243296-303DFC17-6F83-41AB-BD08-1E8E5A937195

Q36243296-30511451-3610-434B-9D28-2F53D31B1BCE

Q36243296-4C64A5AE-DB10-4B6D-BE93-D981BD771ACD

Q36243296-4D553C0C-25AB-4A8A-9E2E-399486E5E439

Q36243296-5130FC27-E133-4081-87CC-F15FC768D5E1

P304

Q36243296-46869C22-CE03-4A09-B1D5-46C3042E671B

P31

Q36243296-1EA3FF2E-2D75-47B8-82AE-B8814B9AA5D7

P356

Q36243296-D713F3A9-F856-4821-9B52-751CB4B76A63

P407

Q36243296-A0B60EF6-BFC2-4E44-899D-5071C191ECDE

P433

Q36243296-04A5AFBE-A425-40AA-AAF9-8898839E22AF

P478

Q36243296-B4ADF403-EC7E-42F0-944F-709F74BEEEBC

P577

Q36243296-97AFC4B8-3B36-4422-8BCA-0B995A5A9267

P5875

Q36243296-E29629C1-5DB3-430B-8F6A-D6A7029EC6C5

P698

Q36243296-E74CED95-D378-4A1D-A0AA-E8AD41F37DDE

P921

Q36243296-5C759002-3BE1-4B99-BB29-99F0426BE80F

P932

Q36243296-1E901251-E231-47B6-88BD-596A74ED0FA7

P356

J.EURURO.2011.11.009

P1433

European Urology

P1476

Biomarkers in the management a ...... ion-resistant prostate cancer.

@en

P2093

A Oliver Sartor

http://www.w3.org/2001/XMLSchema#string

Andrew J Armstrong

http://www.w3.org/2001/XMLSchema#string

Daniel P Petrylak

http://www.w3.org/2001/XMLSchema#string

David M Nanus

http://www.w3.org/2001/XMLSchema#string

Howard I Scher

http://www.w3.org/2001/XMLSchema#string

Mario A Eisenberger

http://www.w3.org/2001/XMLSchema#string

Stephane Oudard

http://www.w3.org/2001/XMLSchema#string

Susan Halabi

http://www.w3.org/2001/XMLSchema#string

P2860

Understanding the Warburg effect: the metabolic requirements of cell proliferation

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases

Abiraterone and increased survival in metastatic prostate cancer

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer

Isolation of circulating tumor cells using a microvortex-generating herringbone-chip.

P304

549-559

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EURURO.2011.11.009

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

61

http://www.w3.org/2001/XMLSchema#string

P577

2011-11-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51813885

http://www.w3.org/2001/XMLSchema#string

P698

22099611

http://www.w3.org/2001/XMLSchema#string

P921

P932

3445625

http://www.w3.org/2001/XMLSchema#string